Replies to post #21566 on Ocata Therapeutics Inc fka OCAT

[rocky301]

dew,


fwiw,

they PR'd the FDA filing on Thursday Nov 19th, the clip below indicates it was filed on the 18th, Wednesday. Using the 19th as the starting count and ending with tomorrow, the 7th, as you stated would put us at 50 days. Nov. 12 days, Dec. 31 days, Jan. 7 days..


"Lanza said ACT decided to target Stargardt’s macular dystrophy first because it has been designated an “orphan disease” and could benefit from a faster regulatory review. The FDA has 30 days to respond to the company’s filing, made Wednesday, and the clinical trial could begin early next year."
http://latimesblogs.latimes.com/booster_shots/2009/11/human-embyronic-stem-cells-stargardts-macular-dystrophy.html